This summer, Professor Sean Tu co-authored eight new articles:
- Prescription Drug Method-of-Use Patent Protection, 1991-2018 in Journal of General Internal Medicine (with Doni Bloomfield, Theodore W. Teng & Aaron S. Kesselheim)
- A response to a letter to the editor in Journal of the American Medical Association (JAMA) regarding his previously-published article, Drug Versioning and Legal Accountability for Preventable Product Harms (with Timothy Bonis)
- Combating Pharmaceutical Patent Thickets in the Trump Administration in Health Affairs Forefront (with Aaron S. Kesselheim & William B. Feldman)
- A response to a letter to the editor in Nature Biotechnology regarding his previously-published article, The Puzzle of Biologics Manufacturing Platform Patents (with Osmat Azzam Jefferson, W. Nicholson Price II, Saurabh Vishnubhakat & Arti K. Rai)
- The Strength and Importance of Government-Funded Patents for Approved Drugs in Nature Biotechnology (with Sarah M.E. Gabriele, Matthew J. Martin & Aaron S. Kesselheim)
- Revenues, Patents, and New Generic Competition for Prescription Drugs in Journal of General Internal Medicine (with Aaron S. Kesselheim, Joseph S. Ross & Ravi Gupta)
- Certification Marks for Supporting Generic Drug Quality in Journal of Law, Medicine & Ethics (with Lars Lindgren & Aaron S. Kesselheim)
- Estimating Costs of Market Exclusivity Extensions For Four Top-Selling Prescription Drugs in the U.S. in JAMA Health Forum (with Dongzhe Hong, Reed F. Beall, Massimiliano Russo, Benjamin N. Rome, Aaron S. Kesselheim & Ameet Sarpatwari).
Professor Tu’s scholarship largely focuses on pharmaceutical patents. You can find more of his articles here.